Page last updated: 2024-11-05

monomethyl succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monomethyl succinate (MMS) is an organic compound with the formula CH3OC(O)CH2CH2C(O)OH. It is a diester, specifically a half-ester of succinic acid. MMS is an important intermediate in the industrial synthesis of succinic acid. It is also a potential biofuel precursor and a valuable building block in organic synthesis. Research on MMS is driven by its potential applications in various fields, including biofuel production, materials science, and pharmaceuticals.'

methylsuccinic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylsuccinic acid : A racemate comprising equimolar amounts of (R)- and (S)-methylsuccinic acid [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-methylbutanedioic acid : A dicarboxylic acid that is butanedioic acid substituted at position 2 by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

monomethyl succinate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

monomethyl succinate : A dicarboxylic acid monoester that is succinic acid in which one of the carboxy groups has been converted to its methyl ester. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10349
CHEBI ID91315
SCHEMBL ID105210
MeSH IDM0122041
PubMed CID77487
CHEBI ID75146
SCHEMBL ID164072
MeSH IDM0122041

Synonyms (114)

Synonym
h1547kg7uz ,
unii-h1547kg7uz
butanedioic acid, 2-methyl-
pyrotartaric acid
2-methylsuccinic acid ,
498-21-5
butanedioic acid, methyl-
nsc-5276
succinic acid, methyl-
1,2-propanedicarboxylic acid
nsc5276
methylsuccinic acid
inchi=1/c5h8o4/c1-3(5(8)9)2-4(6)7/h3h,2h2,1h3,(h,6,7)(h,8,9
nsc 5276
einecs 207-857-1
ccris 6068
2-methylbutanedioic acid
STK301547
methylsuccinic acid, 99%
methyl succinic acid
FT-0690327
M0430
LMFA01170119
2-methyl-butanedioic acid
AKOS003790959
A827865
d,l-2-methylsuccinic acid, 5
bdbm85472
FT-0602059
FT-0605228
S6356
SCHEMBL105210
CHEBI:91315
methylbutanedioic acid
2-methylsuccinicacid
r,s-2-methylbutanedioic acid
(+/-)-methylsuccinic acid
butanedioic acid, methyl-, (+/-)-
dl-.alpha.-methylsuccinic acid
j6.105k ,
dl-methylsuccinic acid
dl-methylbutanedioic acid
2-methylbutane-1,4-dioic acid
(+/-)-.alpha.-methylsuccinic acid
(+/-)-2-methylsuccinic acid
347840-08-8
DTXSID9025663
mfcd00002659
H11814
(r)-(+)-methylsuccinicacid
HY-W010381
CS-W011097
Q27163205
SY036933
AS-17768
SB44814
SY104041
AB89120
4-methoxy-4-oxobutanoic acid
EN300-24949
BB 0254379
einecs 223-408-2
unii-ya2v724s0a
ai3-03389
butanedioic acid, 1-methyl ester
ya2v724s0a ,
nsc 511
methyl hydrogen succinate
succinic acid, monomethyl ester
butanedioic acid, monomethyl ester
3-carbomethoxypropanoic acid
nsc-511
succinic acid monomethyl ester
monomethyl succinate
nsc511
3878-55-5
mono-methyl hydrogen succinate, 95%
butanedioic acid monomethyl ester
mono-methyl hydrogen succinate
STL068961
AKOS000264979
jdrmyoqetpmyqx-uhfffaoysa-
inchi=1/c5h8o4/c1-9-5(8)3-2-4(6)7/h2-3h2,1h3,(h,6,7)
dtxsid7044425 ,
dtxcid5024425
NCGC00257549-01
cas-3878-55-5
tox21_302188
mono-methyl succinate
bdbm82193
3-(methoxycarbonyl)propanoic acid
succinic acid 4-methyl ester
butanedioic acid 1-methyl ester
CHEBI:75146
FT-0618900
AM20100028
SCHEMBL164072
3-methoxycarbonylpropionic acid
monomethyl hydrogen succinate
4-(methyloxy)-4-oxobutanoic acid
4-methoxy-4-oxobutanoic acid #
Z57663583
CS-W011096
J-515649
F1107-0326
mfcd00002788
GS-3418
BP-23493
SY009523
M3262
Q21045268
acidyellow25(c.i.18835)
A855318
butanedioic-13c4acid1-methylester

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours."( Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment.
Dobrowsky, E; Karuri, AR; Tannock, IF, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
hemisuccinateA succinate ester in which only one of the carboxy groups of succinic acid has been esterified.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
proteolysisN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein deglycosylationN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
heme biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
protoporphyrinogen IX biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
heme biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
tetrapyrrole biosynthetic processDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
N4-(beta-N-acetylglucosaminyl)-L-asparaginase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein bindingN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
peptidase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
magnesium ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
porphobilinogen synthase activityDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
zinc ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
lyase activityDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
metal ion bindingDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
extracellular spaceN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
endoplasmic reticulumN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
azurophil granule lumenN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
cytoplasmN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
cytosolDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
cytosolDelta-aminolevulinic acid dehydrataseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1799666Inhibition Assay from Article 10.1080/14756360109162375: \\Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.\\2001Journal of enzyme inhibition, , Volume: 16, Issue:3
Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.
AID1799605PBGS Assay from Article 10.1002/1439-7633(20010504)2: \\Inhibition studies of porphobilinogen synthase from Escherichia coli differentiating between the two recognition sites.\\2001Chembiochem : a European journal of chemical biology, May-04, Volume: 2, Issue:5
Inhibition studies of porphobilinogen synthase from Escherichia coli differentiating between the two recognition sites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (16.28)18.7374
1990's34 (39.53)18.2507
2000's21 (24.42)29.6817
2010's12 (13.95)24.3611
2020's5 (5.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.96 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index32.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (1.64%)6.00%
Case Studies5 (17.86%)4.05%
Case Studies1 (1.64%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other23 (82.14%)84.16%
Other59 (96.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]